{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:30:56Z","timestamp":1791664256816,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["T32 TR004764"],"award-info":[{"award-number":["T32 TR004764"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R42 DA056524"],"award-info":[{"award-number":["R42 DA056524"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA042092"],"award-info":[{"award-number":["R01DA042092"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R37DA039997"],"award-info":[{"award-number":["R37DA039997"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32 GM007767"],"award-info":[{"award-number":["T32 GM007767"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jpet.2026.104942","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:30:58Z","timestamp":1778729458000},"page":"104942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Positive allosteric modulation of the delta opioid receptor attenuates depression-like and pain-like behaviors but does not promote convulsions"],"prefix":"10.1016","volume":"393","author":[{"given":"Emily M.","family":"Jutkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Palleiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac J.","family":"Dripps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard P.","family":"Roques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-0298","authenticated-orcid":false,"given":"Benjamin M.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-8316","authenticated-orcid":false,"given":"John R.","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jpet.2026.104942_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mi.6.3.7","article-title":"The antidepressant -like effects of delta-opioid receptor agonists","volume":"6","author":"Jutkiewicz","year":"2006","journal-title":"Mol Interv"},{"issue":"2\u20133","key":"10.1016\/j.jpet.2026.104942_bib2","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1016\/S0014-2999(98)00933-9","article-title":"Visceral chemical nociception in mice lacking mu-opioid receptors: effects of morphine, SNC80 and U-50,488","volume":"366","author":"Sora","year":"1999","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104942_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1742-7843.2005.pto_97107.x","article-title":"A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80","volume":"97","author":"Gallantine","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104942_bib4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3565(24)38837-8","article-title":"Antinociceptive effects of delta-opioid agonists in Rhesus monkeys: effects on chemically induced thermal hypersensitivity","volume":"296","author":"Brandt","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jpet.2026.104942_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jpain.2011.12.003","article-title":"Effects of the \u03b4 opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats","volume":"13","author":"Negus","year":"2012","journal-title":"J Pain"},{"issue":"10","key":"10.1016\/j.jpet.2026.104942_bib6","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1111\/j.1460-9568.2008.06223.x","article-title":"Inflammatory pain is enhanced in delta opioid receptor-knockout mice","volume":"27","author":"Gav\u00e9riaux-Ruff","year":"2008","journal-title":"Eur J Neurosci"},{"issue":"8","key":"10.1016\/j.jpet.2026.104942_bib7","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/sj.bjp.0703248","article-title":"Antihyperalgesic effects of delta opioid agonists in a rat model of chronic inflammation","volume":"129","author":"Fraser","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104942_bib8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/jpet.102.036525","article-title":"Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice","volume":"303","author":"Broom","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jpet.2026.104942_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3727\/107156998819565947","article-title":"Convulsive behavior of nonpeptide \u03b4-opioid ligands: comparison of SNC80 and BW373U86 in mice","volume":"3","author":"Hong","year":"1998","journal-title":"Analgesia"},{"issue":"2","key":"10.1016\/j.jpet.2026.104942_bib10","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0022-3565(25)39544-3","article-title":"Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice","volume":"267","author":"Comer","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.104942_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00213-002-1179-y","article-title":"Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats","volume":"164","author":"Broom","year":"2002","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.jpet.2026.104942_bib12","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1124\/jpet.105.095810","article-title":"The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol","volume":"317","author":"Jutkiewicz","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jpet.2026.104942_bib13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00213-005-0138-9","article-title":"Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats","volume":"182","author":"Jutkiewicz","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.jpet.2026.104942_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2011.04.041","article-title":"The novel \u03b4 opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions","volume":"223","author":"Saitoh","year":"2011","journal-title":"Behav Brain Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.104942_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/jpet.108.146969","volume":"329","author":"Codd","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jpet.2026.104942_bib16","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1124\/jpet.111.188987","article-title":"\u03b4-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization","volume":"342","author":"Nozaki","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"19","key":"10.1016\/j.jpet.2026.104942_bib17","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1021\/jm8008986","article-title":"Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4\u2019-piperidine]-4-yl)benzamide (ADL5859)","volume":"51","author":"Le Bourdonnec","year":"2008","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.jpet.2026.104942_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/13543784.2017.1275562","article-title":"Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development","volume":"26","author":"Spahn","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"18","key":"10.1016\/j.jpet.2026.104942_bib19","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1021\/jm900773n","article-title":"Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4\u2019-piperidine]-4-yl) benzamide (ADL5747)","volume":"52","author":"Le Bourdonnec","year":"2009","journal-title":"J Med Chem"},{"issue":"49","key":"10.1016\/j.jpet.2026.104942_bib20","doi-asserted-by":"crossref","first-page":"16459","DOI":"10.1523\/JNEUROSCI.3748-10.2010","article-title":"Ligand-directed trafficking of the \u03b4-opioid receptor in vivo: two paths toward analgesic tolerance","volume":"30","author":"Pradhan","year":"2010","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.jpet.2026.104942_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.122.001182","article-title":"Delta opioid receptor-mediated antidepressant-like effects of diprenorphine in mice","volume":"384","author":"Olson","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.jpet.2026.104942_bib22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00213-015-4195-4","article-title":"A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression","volume":"233","author":"Richards","year":"2016","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.jpet.2026.104942_bib23","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1021\/acs.jmedchem.5b00007","article-title":"Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the \u03b4-opioid receptor","volume":"58","author":"Burford","year":"2015","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.jpet.2026.104942_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.117.109561","article-title":"Pharmacologic evidence for a putative conserved allosteric site on opioid receptors","volume":"93","author":"Livingston","year":"2018","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104942_bib25","doi-asserted-by":"crossref","first-page":"G66","DOI":"10.1152\/ajpgi.00297.2021","article-title":"Positive allosteric modulation of endogenous delta opioid receptor signaling in the enteric nervous system is a potential treatment for gastrointestinal motility disorders","volume":"322","author":"DiCello","year":"2022","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jpet.2026.104942_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14611","article-title":"Endogenous opioids regulate moment-to-moment neuronal communication and excitability","volume":"8","author":"Winters","year":"2017","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.jpet.2026.104942_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2000017118","article-title":"Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects","volume":"118","author":"Kandasamy","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jpet.2026.104942_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2026.104304","article-title":"A mu-opioid receptor positive allosteric modulator provides opioid-sparing antinociception without enhancing opioid side effects","volume":"393","author":"Kochan","year":"2026","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jpet.2026.104942_bib29","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0022-3565(24)39189-X","article-title":"BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice","volume":"294","author":"Broom","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"10.1016\/j.jpet.2026.104942_bib30","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1021\/jm00091a016","article-title":"\u201cMixed inhibitor-prodrug\u201d as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes","volume":"35","author":"Fournie-Zaluski","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpet.2026.104942_bib31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.brainres.2005.12.066","article-title":"Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes","volume":"1073\u20131074","author":"Lester","year":"2006","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.jpet.2026.104942_bib32","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"6","key":"10.1016\/j.jpet.2026.104942_bib33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bph.14131","article-title":"Role of signalling molecules in behaviours mediated by the \u03b4 opioid receptor agonist SNC80","volume":"175","author":"Dripps","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104942_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J Neurosci Methods"},{"issue":"4","key":"10.1016\/j.jpet.2026.104942_bib35","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0026-895X(25)08634-1","article-title":"Modulation by mu-opioid agonists of guanosine-5\u2032-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells","volume":"47","author":"Traynor","year":"1995","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104942_bib36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0893-133X(01)00413-4","article-title":"Nonpeptidic \u03b4-opioid receptor agonists reduce immobility in the forced swim assay in rats","volume":"26","author":"Broom","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jpet.2026.104942_bib37","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1254\/jphs.FPJ04014X","article-title":"Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents","volume":"95","author":"Saitoh","year":"2004","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.jpet.2026.104942_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1527-3458.2007.00011.x","article-title":"RB101-mediated protection of endogenous opioids: potential therapeutic utility?","volume":"13","author":"Jutkiewicz","year":"2007","journal-title":"CNS Drug Rev"},{"issue":"1","key":"10.1016\/j.jpet.2026.104942_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/acschemneuro.4c00541","article-title":"Structure-activity relationships and molecular pharmacology of positive allosteric modulators of the mu-opioid receptor","volume":"16","author":"Li","year":"2025","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104942_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00213-016-4432-5","article-title":"The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors","volume":"234","author":"Dripps","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"10.1016\/j.jpet.2026.104942_bib41","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bph.14602","article-title":"The \u03b4-opioid receptor positive allosteric modulator BMS 986187 is a G-protein-biased allosteric agonist","volume":"176","author":"Stanczyk","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104942_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0306-4530(01)00052-X","article-title":"Amplified behavioral and endocrine responses to forced swim stress in the Wistar-Kyoto rat","volume":"27","author":"Rittenhouse","year":"2002","journal-title":"Psychoneuroendocrinology"},{"issue":"2\u20133","key":"10.1016\/j.jpet.2026.104942_bib43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ejphar.2010.10.050","article-title":"Stress-induced analgesia and endogenous opioid peptides: the importance of stress duration","volume":"650","author":"Parikh","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104942_bib44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0031-9384(82)90070-1","article-title":"Involvement of endogenous opioids with forced swimming-induced immobility in mice","volume":"28","author":"Amir","year":"1982","journal-title":"Physiol Behav"},{"issue":"14","key":"10.1016\/j.jpet.2026.104942_bib45","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/WNR.0b013e32830dd655","article-title":"Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1\/2","volume":"19","author":"Bruchas","year":"2008","journal-title":"Neuroreport"},{"issue":"8","key":"10.1016\/j.jpet.2026.104942_bib46","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/sj.npp.1300934","article-title":"Dissociation of analgesic and hormonal responses to forced swim stress using opioid receptor knockout mice","volume":"31","author":"Contet","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jpet.2026.104942_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends Neurosci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104942_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0022-3565(25)09569-2","article-title":"SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist","volume":"273","author":"Bilsky","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.jpet.2026.104942_bib49","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.3892\/etm.2015.2407","article-title":"Analgesic roles of peripheral intrinsic met-enkephalin and dynorphin A in long-lasting inflammatory pain induced by complete Freund\u2019s adjuvant in rats","volume":"9","author":"Jiang","year":"2015","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.jpet.2026.104942_bib50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0006-8993(85)90096-4","article-title":"Spontaneous and evoked release of methionine-enkephalin-like material from the rat spinal cord in vivo","volume":"339","author":"Cesselin","year":"1985","journal-title":"Brain Res"},{"issue":"9","key":"10.1016\/j.jpet.2026.104942_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.molpha.2025.100068","article-title":"Biasing G protein \u03b2\u03b3 subunit downstream signaling enhances the analgesic effects of endogenous opioid receptor agonists during nitroglycerin-induced thermal hypersensitivity","volume":"107","author":"Mohamed","year":"2025","journal-title":"Mol Pharmacol"},{"issue":"9","key":"10.1016\/j.jpet.2026.104942_bib52","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/bph.12591","article-title":"\u03b4-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice","volume":"171","author":"Pradhan","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104942_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-3565(25)24991-6","article-title":"U50,488, a highly selective kappa opioid: anticonvulsant profile in rats","volume":"237","author":"Tortella","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2026.104942_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2023.137477","article-title":"Effect of U50488, a selective kappa opioid receptor agonist and levetiracetam against lithium-pilocarpine-induced status epilepticus, spontaneous convulsive seizures and related cognitive impairment","volume":"815","author":"Kumar","year":"2023","journal-title":"Neurosci Lett"},{"issue":"11","key":"10.1016\/j.jpet.2026.104942_bib55","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/hipo.20633","article-title":"Dynamic up-regulation of prodynorphin transcription in temporal lobe epilepsy","volume":"19","author":"Pirker","year":"2009","journal-title":"Hippocampus"},{"issue":"4","key":"10.1016\/j.jpet.2026.104942_bib56","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/brain\/awl384","article-title":"Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors","volume":"130","author":"Loacker","year":"2007","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.jpet.2026.104942_bib57","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pharmthera.2009.05.006","article-title":"30 Years of dynorphins\u2013new insights on their functions in neuropsychiatric diseases","volume":"123","author":"Schwarzer","year":"2009","journal-title":"Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.jpet.2026.104942_bib58","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1523\/JNEUROSCI.23-13-05674.2003","article-title":"Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses","volume":"23","author":"McLaughlin","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.jpet.2026.104942_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.914651","article-title":"Exploration of beta-arrestin isoform signaling pathways in delta opioid receptor agonist-induced convulsions","volume":"13","author":"Blaine","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104942_bib60","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/npp.2013.342","article-title":"Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?","volume":"39","author":"Belzung","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.jpet.2026.104942_bib61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jpain.2004.12.006","article-title":"Gonadal hormone modulation of mu, kappa, and delta opioid antinociception in male and female rats","volume":"6","author":"Stoffel","year":"2005","journal-title":"J Pain"},{"key":"10.1016\/j.jpet.2026.104942_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104522","article-title":"Sex differences in opioid receptor mediated effects: role of androgens","volume":"134","author":"Sharp","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jpet.2026.104942_bib63","doi-asserted-by":"crossref","unstructured":"Mobbs JI, Nguyen MD, Deo O, et al. Structure-guided allosteric modulation of the delta opioid receptor. Preprint. Posted online October 17, 2015. bioRxiv 682975. https:\/\/doi.org\/10.1101\/2025.10.16.682975","DOI":"10.1101\/2025.10.16.682975"},{"issue":"7","key":"10.1016\/j.jpet.2026.104942_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aea9832","article-title":"Structure-based design of an opioid receptor modulator for enhanced morphine analgesia","volume":"12","author":"Wang","year":"2026","journal-title":"Sci Adv"},{"issue":"15","key":"10.1016\/j.jpet.2026.104942_bib65","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1021\/acschemneuro.5c00280","article-title":"A structure-activity relationship study of novel positive allosteric modulators for the \u03b4-opioid receptor","volume":"16","author":"Deo","year":"2025","journal-title":"ACS Chem Neurosci"},{"issue":"18","key":"10.1016\/j.jpet.2026.104942_bib66","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.1021\/acs.jmedchem.2c01061","article-title":"The design, synthesis, and evaluation of novel 9-arylxanthenedione-based allosteric modulators for the \u03b4-opioid receptor","volume":"65","author":"Deo","year":"2022","journal-title":"J Med Chem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:20:41Z","timestamp":1785399641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526011419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0022356526011419"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104942","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positive allosteric modulation of the delta opioid receptor attenuates depression-like and pain-like behaviors but does not promote convulsions","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104942"}}